These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 8917738)

  • 41. Differences in immunoglobulin preparations and outcome of Kawasaki disease.
    Yavuz H; Ozel A
    J Pediatr; 1996 May; 128(5 Pt 1):719-20. PubMed ID: 8627453
    [No Abstract]   [Full Text] [Related]  

  • 42. A pediatric case series of acute hemolysis after administration of intravenous immunoglobulin.
    Gordon DJ; Sloan SR; de Jong JL
    Am J Hematol; 2009 Nov; 84(11):771-2. PubMed ID: 19806664
    [No Abstract]   [Full Text] [Related]  

  • 43. Lambert-Eaton myasthenic syndrome: Epidemiology and therapeutic response in the national veterans affairs population.
    Abenroth DC; Smith AG; Greenlee JE; Austin SD; Clardy SL
    Muscle Nerve; 2017 Sep; 56(3):421-426. PubMed ID: 27997683
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immune supplementation and immune modulation with intravenous immunoglobulin.
    Mazer BD; Al-Tamemi S; Yu JW; Hamid Q
    J Allergy Clin Immunol; 2005 Oct; 116(4):941-4. PubMed ID: 16210080
    [No Abstract]   [Full Text] [Related]  

  • 45. Long-term observation of incremental response and antibodies to voltage-gated calcium channels in patients with Lambert-Eaton myasthenic syndrome: two case reports.
    Schneider I; Kornhuber ME; Hanisch F
    J Med Case Rep; 2015 Mar; 9():59. PubMed ID: 25885033
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome.
    Rees JH
    J Neurol Neurosurg Psychiatry; 1998 Feb; 64(2):148-9. PubMed ID: 9489520
    [No Abstract]   [Full Text] [Related]  

  • 47. Marked pleural effusion after i.v. immunoglobulin therapy for Kawasaki disease.
    Koizumi K; Hoshiai M; Toda T; Nakane T; Sugita K
    Pediatr Int; 2018 Mar; 60(3):307-308. PubMed ID: 29480538
    [No Abstract]   [Full Text] [Related]  

  • 48. Intravenous gammaglobulin, 2: Pharmacology, clinical uses and mechanisms of action.
    Schiff RI
    Pediatr Allergy Immunol; 1994 Aug; 5(3):127-56. PubMed ID: 7951755
    [No Abstract]   [Full Text] [Related]  

  • 49. Changes in BAFF/APRIL levels in a 2-year-old girl with Kawasaki disease refractory to intravenous immunoglobulin therapy.
    Yoshida S; Sakurai Y; Takeda T; Fukuda K
    J Investig Allergol Clin Immunol; 2013; 23(1):52-3. PubMed ID: 23653975
    [No Abstract]   [Full Text] [Related]  

  • 50. Kawasaki disease.
    Sundel RP
    Rheum Dis Clin North Am; 2015; 41(1):63-73, viii. PubMed ID: 25399940
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The safety of immune globulins.
    Tepper M; Gully P
    Can Commun Dis Rep; 1996 Jul; 22(14):117-9. PubMed ID: 8754937
    [No Abstract]   [Full Text] [Related]  

  • 52. Treatment of childhood dermatomyositis with high dose intravenous immunoglobulin.
    Vedanarayanan V; Subramony SH; Ray LI; Evans OB
    Pediatr Neurol; 1995 Nov; 13(4):336-9. PubMed ID: 8771171
    [TBL] [Abstract][Full Text] [Related]  

  • 53. NIH consensus conference. Intravenous immunoglobulin. Prevention and treatment of disease.
    JAMA; 1990 Dec; 264(24):3189-93. PubMed ID: 2255028
    [No Abstract]   [Full Text] [Related]  

  • 54. Treatment of Lambert-Eaton syndrome with intravenous immunoglobulin.
    Rich MM; Teener JW; Bird SJ
    Muscle Nerve; 1997 May; 20(5):614-5. PubMed ID: 9140371
    [No Abstract]   [Full Text] [Related]  

  • 55. Both patient characteristics and IVIG product-specific mechanisms may affect eosinophils in immunoglobulin-treated Kawasaki disease.
    Khan S; Doré PC; Sewell WA
    Pediatr Allergy Immunol; 2008 Mar; 19(2):186-7. PubMed ID: 18257907
    [No Abstract]   [Full Text] [Related]  

  • 56. Management of Kawasaki disease in resource-limited settings.
    Singh S; Newburger JW; Kuijpers T; Burgner D
    Pediatr Infect Dis J; 2015 Jan; 34(1):94-6. PubMed ID: 25741801
    [No Abstract]   [Full Text] [Related]  

  • 57. Clinical application of rapid assay of serum interleukin-6 in Kawasaki disease.
    Suganami Y; Kawashima H; Hasegawa D; Sato S; Hoshika A
    Pediatr Int; 2008 Apr; 50(2):264-6. PubMed ID: 18353077
    [No Abstract]   [Full Text] [Related]  

  • 58. Treatment of Kawasaki disease.
    Glode MP; Burns JC
    Pediatr Infect Dis J; 1992 Mar; 11(3):249-50. PubMed ID: 1565549
    [No Abstract]   [Full Text] [Related]  

  • 59. Treatment of a Jehovah's Witness with immune globulin: case of a child with Kawasaki syndrome.
    Roy-Bornstein C; Sagor LD; Roberts KB
    Pediatrics; 1994 Jul; 94(1):112-3. PubMed ID: 8008516
    [No Abstract]   [Full Text] [Related]  

  • 60. [Cholestatic hepatitis in immunoglobulin-resistant Kawasaki disease].
    Vázquez Gomis R; Izquierdo Fos I; López Yañez A; Mendoza Durán M; Serrano Robles MI; Vázquez Gomis C; Pastor Rosado J
    Gastroenterol Hepatol; 2016 Apr; 39(4):301-2. PubMed ID: 26749080
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.